AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10194170 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium salicylate (SSA)
Number of subjects: 0
Study 10194170 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LASA)
Number of subjects: 0
Study 10194170 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0
Study 10194170 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 7780288 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 37
Study 7780288 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 37
Study 2194652 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous infusion of methotrexate and teniposide
Number of subjects: 19
Study 2194652 — intervention group
Group type: COMPARATOR
Intervention: Sequential infusion of methotrexate followed by teniposide
Number of subjects: 19
Study 344012 — intervention group
Group type: COMPARATOR
Intervention: Sch 1000 (200 microgram)
Number of subjects: 24
Study 344012 — intervention group
Group type: COMPARATOR
Intervention: Sch 1000 (400 microgram)
Number of subjects: 24
Study 31333114 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine
Number of subjects: 62
Study 31333114 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 62
Study 31333114 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl
Number of subjects: 62
Study 31333114 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine
Number of subjects: 62
Study 31333114 — intervention group
Group type: EXPERIMENTAL
Intervention: All opioids
Number of subjects: 62
Study 26053503 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic chlorhexidine‐based gingiva‐adhering gel (applied once every second day for 14 days)
Number of subjects: 34
Study 26053503 — intervention group
Group type: COMPARATOR
Intervention: 1% chlorhexidine water‐soluble gel (applied twice daily)
Number of subjects: 34
Study 25373742 — intervention group
Group type: EXPERIMENTAL
Intervention: SEBT grid training
Number of subjects: 60
Study 25373742 — intervention group
Group type: COMPARATOR
Intervention: Stationary cycling (Control)
Number of subjects: 60
Study 23529567 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5 mg/day
Number of subjects: 597
Study 23529567 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg/day
Number of subjects: 597
Study 23529567 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 597
Study 23529567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 597
Study 21318011 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked randomization with randomly selected block sizes
Number of subjects: 0
Study 21318011 — intervention group
Group type: COMPARATOR
Intervention: Simple random allocation scheme
Number of subjects: 0
Study 19556470 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise (NE) training program
Number of subjects: 74
Study 19556470 — intervention group
Group type: COMPARATOR
Intervention: Strength exercise (SE) training program
Number of subjects: 74
Study 16030082 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar epidural corticosteroid injections (ESI) of triamcinolone acetonide, administered three times at intervals of 3 weeks.
Number of subjects: 228
Study 16030082 — intervention group
Group type: COMPARATOR
Intervention: Interligamentous saline injections (placebo control), administered three times at intervals of 3 weeks.
Number of subjects: 228
Study 12042368 — intervention group
Group type: EXPERIMENTAL
Intervention: N(G)‐monomethyl‐L‐arginine (L‐NMMA) (3 mg kg(‐1))
Number of subjects: 9
Study 12042368 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 9
Study 12042368 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (100 microg)
Number of subjects: 9
Study 10064291 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention discussing maternal distress and infant difficulty
Number of subjects: 78
Study 7674244 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAMCARE (team managed outpatient care program)
Number of subjects: 118
Study 7674244 — intervention group
Group type: COMPARATOR
Intervention: TRADCARE (traditional nonteam managed rheumatologic care)
Number of subjects: 118
Study 7674244 — intervention group
Group type: COMPARATOR
Intervention: TEAMCARE and TRADCARE
Number of subjects: 118
Study 2275890 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study 2275890 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 2275890 — intervention group
Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 0
Study 7029318 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril therapy
Number of subjects: 16
Study 7029318 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol therapy
Number of subjects: 16
Study 31564317 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost administration
Number of subjects: 156
Study 31564317 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of latanoprost
Number of subjects: 156
Study 28417704 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nitrate cauterization of the left middle turbinate (MT)
Number of subjects: 38
Study 28417704 — intervention group
Group type: COMPARATOR
Intervention: Control (noncauterized right middle turbinate)
Number of subjects: 38
Study 26444095 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 210
Study 26444095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 23808222 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative photodynamic therapy (PhT) using chlorine E6 and light of wavelength 662 nm
Number of subjects: 42
Study 23808222 — intervention group
Group type: COMPARATOR
Intervention: Control group without photodynamic therapy (PhT)
Number of subjects: 42
Study 23808222 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative photodynamic therapy (PhT)
Number of subjects: 42
Study 21920260 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer drug-eluting stents (n = 1,299)
Number of subjects: 2603
Study 21920260 — intervention group
Group type: COMPARATOR
Intervention: Permanent polymer drug-eluting stents (n = 1,304)
Number of subjects: 2603
Study 21920260 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES) (n = 652)
Number of subjects: 2603
Study 21920260 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES) (n = 652)
Number of subjects: 2603
Study 19810365 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinonic acid
Number of subjects: 100
Study 19810365 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide
Number of subjects: 100
Study 19810365 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 100
Study 19810365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleanser
Number of subjects: 100
Study 19810365 — intervention group
Group type: EXPERIMENTAL
Intervention: All four medications
Number of subjects: 100
Study 16500018 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% oxygen (group A)
Number of subjects: 28
Study 16500018 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen (group B)
Number of subjects: 28
Study 15572523 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple breath-hold averaged (1)H-MRS at high field (3T) in renal cell carcinoma tumors
Number of subjects: 24
Study 15572523 — intervention group
Group type: COMPARATOR
Intervention: Multiple breath-hold averaged (1)H-MRS at high field (3T) in healthy kidneys
Number of subjects: 24
Study 12177646 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 317
Study 12177646 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone treatment
Number of subjects: 317
Study 12177646 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy with > or =5 shocks
Number of subjects: 317
Study 9952095 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine sodium benzoate (500 mg) in 1,000 mL normal saline
Number of subjects: 60
Study 9952095 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo) in 1,000 mL
Number of subjects: 60
Study 8525855 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic assessment and child video recording observation
Number of subjects: 10
Study 2259226 — intervention group
Group type: EXPERIMENTAL
Intervention: DA (daunorubicin 45 mg/m2/day x 3)
Number of subjects: 299
Study 2259226 — intervention group
Group type: EXPERIMENTAL
Intervention: MA (m-AMSA 200 mg/m2/day x 3 days)
Number of subjects: 299
Study 2259226 — intervention group
Group type: EXPERIMENTAL
Intervention: MA (m-AMSA)
Number of subjects: 299
Study 2259226 — intervention group
Group type: EXPERIMENTAL
Intervention: DA (daunorubicin)
Number of subjects: 299
Study 2259226 — intervention group
Group type: COMPARATOR
Intervention: No maintenance
Number of subjects: 299
Study 2259226 — intervention group
Group type: EXPERIMENTAL
Intervention: DA every 13 weeks x 4 cycles
Number of subjects: 299
Study 2259226 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous relapse-free survivors
Number of subjects: 299
Study 7402449 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg naloxone
Number of subjects: 0
Study 7402449 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study 31282447 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) intervention
Number of subjects: 71
Study 31282447 — intervention group
Group type: COMPARATOR
Intervention: Sham chamber sessions (control)
Number of subjects: 71
Study 31282447 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 71
Study 28192477 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pharmacist-led medication review
Number of subjects: 10407
Study 28192477 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pharmacist-led medication review (for patients under 80 years)
Number of subjects: 10407
Study 28192477 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10407
Study 26486192 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 351
Study 26486192 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 351
Study 26486192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 26486192 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo)
Number of subjects: 351
Study 26486192 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg and 300 mg
Number of subjects: 351
Study 24256460 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate dressing (BMV)
Number of subjects: 324
Study 24256460 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol-betamethasone dipropionate ointment (CBD)
Number of subjects: 324
Study 24256460 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BMV and CBD
Number of subjects: 324
Study 23021506 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD-CV co-administered with routine childhood vaccines
Number of subjects: 230
Study 19782914 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective inhibitors of factor Xa and thrombin
Number of subjects: 0
Study 19782914 — intervention group
Group type: COMPARATOR
Intervention: Conventional anticoagulants (heparins and vitamin K antagonists)
Number of subjects: 0
Study 17313293 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐mg x kg(‐1) dose of caffeine
Number of subjects: 20
Study 17313293 — intervention group
Group type: COMPARATOR
Intervention: 3‐mg x kg(‐1) dose of caffeine
Number of subjects: 20
Study 17313293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15360029 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete pressure relief (5 mm Hg)
Number of subjects: 28
Study 15360029 — intervention group
Group type: COMPARATOR
Intervention: Partial pressure relief (20 mm Hg)
Number of subjects: 28
Study 15360029 — intervention group
Group type: EXPERIMENTAL
Intervention: Full pressure relief (0 mm Hg)
Number of subjects: 28
Study 11677377 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan + Hydrochlorothiazide (12.5 mg/day)
Number of subjects: 327
Study 11677377 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan + Benazepril (10 mg/day)
Number of subjects: 327
Study 11677377 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (80 mg/day) alone
Number of subjects: 327
Study 9674442 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabolic steroids (250 mg testosterone i.m. at baseline and 12 mg oral stanozolol daily for 27 weeks)
Number of subjects: 23
Study 9674442 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabolic steroids
Number of subjects: 23
Study 9674442 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 23
Study 8023059 — intervention group
Group type: EXPERIMENTAL
Intervention: DFO (Deferoxamine) at a low dose of 10 mg/kg body weight per week
Number of subjects: 10
Study 8023059 — intervention group
Group type: COMPARATOR
Intervention: Cuprophan membrane CF1511
Number of subjects: 10
Study 8023059 — intervention group
Group type: COMPARATOR
Intervention: Polysulfone membrane F60
Number of subjects: 10
Study 8023059 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate and calcium acetate phosphate binders
Number of subjects: 10
Study 8023059 — intervention group
Group type: COMPARATOR
Intervention: Regular controls of plasma aluminium levels
Number of subjects: 10
Study 2587017 — intervention group
Group type: EXPERIMENTAL
Intervention: Solcoseryl eye drops
Number of subjects: 94
Study 2587017 — intervention group
Group type: COMPARATOR
Intervention: Vitasic eye drops
Number of subjects: 94
Study 4938640 — intervention group
Group type: EXPERIMENTAL
Intervention: Marihuana
Number of subjects: 0
Study 30102051 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAPT (After Deployment Adaptive Parenting Tools), a 14-week group-based intervention
Number of subjects: 336
Study 30102051 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 336
Study 27287201 — intervention group
Group type: EXPERIMENTAL
Intervention: SVelter algorithm for resolving complex chromosomal rearrangements
Number of subjects: 0
Study 24628437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-pocket lidocaine and prilocaine gel (2.5% each)
Number of subjects: 38
Study 24628437 — intervention group
Group type: COMPARATOR
Intervention: Injected articaine (1:100,000 adrenaline)
Number of subjects: 38
Study 22669588 — intervention group
Group type: EXPERIMENTAL
Intervention: UC-HDF
Number of subjects: 30
Study 22669588 — intervention group
Group type: COMPARATOR
Intervention: sOL-HDF
Number of subjects: 30
Study 20488929 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid morphine (group SAM; n = 28)
Number of subjects: 57
Study 18663493 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative maxillo-mandibular fixation (MMF) for 13 patients for 1 week after SSRO
Number of subjects: 27
Study 18663493 — intervention group
Group type: COMPARATOR
Intervention: No postoperative maxillo-mandibular fixation for 14 patients, occlusal guidance with elastics starting from the third postoperative day
Number of subjects: 27
Study 18663493 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MMF and no MMF)
Number of subjects: 27
Study 16146573 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant supported dentures
Number of subjects: 117
Study 16146573 — intervention group
Group type: COMPARATOR
Intervention: High quality conventional dentures
Number of subjects: 117
Study 12460093 — intervention group
Group type: EXPERIMENTAL
Intervention: Information plus interview group
Number of subjects: 894
Study 12460093 — intervention group
Group type: EXPERIMENTAL
Intervention: Information alone group
Number of subjects: 894
Study 12460093 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 894
Study 10063488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 g/kg)
Number of subjects: 20
Study 10063488 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (0.2 g/kg)
Number of subjects: 20
Study 10063488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol administration
Number of subjects: 20
Study 7726267 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg single oral dose
Number of subjects: 429
Study 7726267 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole 100 mg vaginal treatment for 7 days
Number of subjects: 429
Study 2185294 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (Timunox, n = 48)
Number of subjects: 100
Study 2185294 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 52)
Number of subjects: 100
Study 7021058 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate dentifrice
Number of subjects: 27
Study 7021058 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 27
Study 31035665 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Amplitude Seizure Therapy (LAP‐ST) at 500mA
Number of subjects: 7
Study 31035665 — intervention group
Group type: COMPARATOR
Intervention: Standard Right Unilateral Electroconvulsive Therapy (RUL ECT) at 900 mA
Number of subjects: 7
Study 29111172 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling plus oral nutritional supplements (ONS)
Number of subjects: 159
Study 29111172 — intervention group
Group type: COMPARATOR
Intervention: Nutritional counseling without oral nutritional supplements (ONS)
Number of subjects: 159
Study 27389341 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-Infant Bonding Questionnaire (MIBQ)
Number of subjects: 751
Study 25268205 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone (cohort 1)
Number of subjects: 0
Study 25268205 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with a monoclonal antibody (cohort 2)
Number of subjects: 0
Study 25268205 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection of metastasis (cohort 1)
Number of subjects: 0
Study 25268205 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection of metastasis (cohort 2)
Number of subjects: 0
Study 22473458 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of valsartan and captopril
Number of subjects: 116
Study 22473458 — intervention group
Group type: COMPARATOR
Intervention: Captopril alone (ACEI group)
Number of subjects: 116
Study 22473458 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional ARB therapy
Number of subjects: 116
Study 20413119 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17609871 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy with razoxane (group B)
Number of subjects: 36
Study 17609871 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (group A)
Number of subjects: 36
Study 16223969 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy plus medical management for medication taper (CBT-MM)
Number of subjects: 42
Study 16223969 — intervention group
Group type: COMPARATOR
Intervention: Medical management alone (MM)
Number of subjects: 42
Study 12407044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer (group 1)
Number of subjects: 184
Study 12407044 — intervention group
Group type: COMPARATOR
Intervention: Clinical touch embryo transfer (group 2)
Number of subjects: 184
Study 11086670 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Support Engineering Ltd. (LSEL) mask
Number of subjects: 10
Study 11086670 — intervention group
Group type: EXPERIMENTAL
Intervention: Zvezda Enterprise (ZE) mask
Number of subjects: 10
Study 11086670 — intervention group
Group type: EXPERIMENTAL
Intervention: Duke prototype mask
Number of subjects: 10
Study 8957641 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier cream with particles
Number of subjects: 0
Study 8957641 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer
Number of subjects: 0
Study 8957641 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone-containing cream
Number of subjects: 0
Study 1349458 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (20 or 40 mg/day)
Number of subjects: 19
Study 1349458 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol (10 or 20 mg/day)
Number of subjects: 19
Study 1349458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3993545 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/day)
Number of subjects: 47
Study 3993545 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 47
Study 3993545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 29946115 — intervention group
Group type: EXPERIMENTAL
Intervention: Red palm olein
Number of subjects: 53
Study 29946115 — intervention group
Group type: COMPARATOR
Intervention: Palm olein
Number of subjects: 53
Study 29728195 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium oxalate mouthrinse (KO)
Number of subjects: 375
Study 29728195 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 375
Study 27579360 — intervention group
Group type: EXPERIMENTAL
Intervention: Peyton's 4-Steps-Approach (PEY)
Number of subjects: 134
Study 27579360 — intervention group
Group type: EXPERIMENTAL
Intervention: Peyton's 4-Steps-Approach without Step 3 (PMOD)
Number of subjects: 134
Study 27579360 — intervention group
Group type: COMPARATOR
Intervention: Standard model (STDM)
Number of subjects: 134
Study 24051391 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoven (Fresenius‐Kabi AG, Bad Homburg, Germany)
Number of subjects: 217
Study 24051391 — intervention group
Group type: EXPERIMENTAL
Intervention: Diprivan (Astra‐Zeneca, Cheshire, United Kingdom)
Number of subjects: 217
Study 24051391 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipuro (B‐Braun, Melshungen AG, Germany)
Number of subjects: 217
Study 24051391 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% mixed with propofol formulations
Number of subjects: 217
Study 24051391 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 217
Study 24063608 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 100